A Phase 2 interventional study of Palbociclib and Temozolomide in Ewing Sarcoma, Solid Tumors and Rhabdoid Tumor, sponsored by Pfizer. Completed at 84 sites in 13 countries. Open to participants aged 2 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing temozolomide in Sarcoma, Ewing — 3 open to participants now, 5 under way, none of them phase 3. Temozolomide · Sarcoma, Ewing.
Among the 14 studies testing temozolomide in Sarcoma, Ewing, this one has the largest enrollment, is the only one that started in 2019, is one of 8 in phase 2, and was the 9th registered.
250 studies on the registry are indexed under Sarcoma, Ewing; 69 are open to participants now.
Browse Sarcoma, Ewing studies →3 of the 14 studies testing temozolomide in Sarcoma, Ewing are open now, in 3 countries. Recruiting first, the newest first:
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 1+
Sun Yat-sen University · Sites in China
Ages 18–75
St. Jude Children's Research Hospital · Sites in United States, Canada
Ages 12 mo–30 yrs
By country, each count listing its studies:
Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 58 Sarcoma, Ewing studies recruiting now, 19 (33%) set no upper age limit and 36 (62%) stop at 75 or younger; 49 take children under 18; 2 take healthy volunteers.
This study: 2 Years to 20 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 1
First in 2006; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 128 is above the median of 36 across 204 interventional studies indexed under Sarcoma, Ewing.
Median enrollment 39 across the 14 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 4 studies filed under Sarcoma, Ewing — fewer than ten, so there is no comparison to draw.
3 of the studies testing temozolomide in Sarcoma, Ewing that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04901702St. Jude Children's Research HospitalStudy of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | 2026-12-31 |
| NCT06827717Sun Yat-sen UniversityPhase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma | 2027-04 |
| NCT01864109Memorial Sloan Kettering Cancer CenterIrinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies testing temozolomide in Sarcoma, Ewing, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults with recurrent or refractory solid tumors (phase 1). Neuroblastoma tumor specific cohort to further evaluate antitumor activity of palbociclib in combination with topotecan and cyclophosphamide in children, adolescents, and young adults with recurrent or refractory neuroblastoma. Phase 2 to learn about the efficacy of palbociclib in combination with irinotecan and temozolomide when compared with irinotecan and temozolomide alone in the treatment of children, adolescents, and young adults with recurrent or refractory Ewing sarcoma (EWS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
confirmed solid tumor as follows:
Adequate bone marrow function.
Adequate liver function, including:
(AST) and alanine aminotransferase (ALT)
≤2.5 × (ULN) or ≤5 × ULN for age, if attributable to disease involvement of the liver;
Patients enrolled to Phase 1 portion of the study and tumor specific cohorts must have as defined by version 1.1 or modified RANO criteria for CNS disease or at least evaluable disease by INRC for neuroblastoma.
The eligible patients with neuroblastoma must have at least one of the following at the time of study entry:
Patients with EWS enrolled to Phase 2 portion of the study are eligible with evaluable disease (eg, bone only disease with no soft tissue component).
Exclusion:
History of or uncontrolled cardiac disease, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Palbociclib in combination with topotecan and cyclophosphamide.
Drug: Palbociclib · Drug: Topotecan · Drug: Cyclophosphamide
Palbociclib in combination with temozolomide and irinotecan and/or with topotecan and cyclophosphamide.
Drug: Palbociclib · Drug: Temozolomide · Drug: Irinotecan · Drug: Topotecan · Drug: Cyclophosphamide
Palbociclib in combination with irinotecan and temozolomide.
Drug: Palbociclib · Drug: Temozolomide · Drug: Irinotecan
Irinotecan and temozolomide alone.
Drug: Temozolomide · Drug: Irinotecan
Phase 1: Administered (oral) at 55 mg/m2, 75 mg/m2, or 40 mg/m2, or 95 mg/m2 or 115 mg/m2 on days 1-14 of a 21-day cycle Phase 1 Tumor specific cohort-Neuroblastoma and Phase 2 : Administered (oral) at 75 mg/m2 on days 1-14 of a 21-day cycle
Also known as: Ibrance
Phase 1 and Phase 2: Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle
Also known as: Temodar
Phase 1 and Phase 2: Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
Also known as: Campto
Phase 1 only : Administered at 0.75 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
Also known as: Hycamtin
Phase 1 only: Administered at 250 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
Also known as: Cytoxan
Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs)
DLT was an adverse event (AE) occurring in the first cycle of treatment which were attributable to at least one of the agents in the combination that met the defined criteria of study per Sponsor. An AE we defined as any untoward medical occurrence in a study participant who received study drug without regard to possibility of causal relationship. AEs determined as DLT were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Time frame: Cycle 1 (21 days)
Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Treatment-emergent AEs, Treatment-emergent Serious AEs (SAEs), Treatment Related AEs, Treatment Related SAEs and AEs of Maximum Grade 3 or 4 and 5
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs: AEs that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect or other important medical event. Treatment-emergent AEs: AEs that occurred on or after the first dose of study treatment and up to 35 days after last dose of study treatment. AEs related to study drug as judged by the investigator were considered as treatment-related TEAEs. Severity of AEs were graded according to CTCAE version 4.03 as: Grade 3= severe, Grade 4= life threatening, and Grade 5= death related to AE.
Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Maximum CTCAE Grade in Hematology Parameters
Hematology parameters included activated partial thromboplastin time prolonged, anemia, hemoglobin increased, international normalized ratio (INR) increased, lymphocyte count decreased and increased, neutrophil count decreased, platelet count decreased. Grades by CTCAE version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening and Grade 5= death related to AE; Grade 0= non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter.
Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Maximum CTCAE Grade in Chemistry Parameters
Clinical chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia and hypophosphatemia. According to CTCAE version 4.03: Grade 1=mild, Grade 2=moderate, Grade 3=severe and Grade 4= life-threatening; Grade 0: non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter.
Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Post-Baseline and Maximum Change From Baseline in Electrocardiogram (ECG) Parameters
ECG parameters included PR interval, QRS complex, QT interval, Bazett's correction QT (QTcB) interval and Fridericia's correction (QTcF) interval. In this outcome measure number of participants with post-baseline values and with maximum change from baseline values in ECG parameters were recorded.
Time frame: Baseline (pre-treatment) up to Cycle 3 (63 days)
Phase 1, Dose Expansion Cohorts and TSC: Maximum Change From Baseline in Vital Signs Parameter- Blood Pressure
Blood pressure evaluation included systolic blood pressure (SBP) and diastolic blood pressure (DBP). SBP and DBP were measured in the sitting position after participant had been in the supine position for approximately 2 minutes.
Time frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 24.2 months)
Phase 1, Dose Expansion Cohorts and TSC: Maximum Change From Baseline in Vital Signs Parameter- Pulse Rate
Pulse rate was measured in a supine position using an automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without any distractions.
Time frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 25 months)
Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Clinically Significant Changes in Glycosylated Hemoglobin (HbA1c)
HbA1c is a form of hemoglobin which was measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Clinical significance was determined based on investigator
Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
Phase 1, Dose Expansion Cohorts: Objective Response (OR) Rate Based on Investigator Assessment
OR: best overall response(BOR) of confirmed complete response(CR) or partial response(PR) per response evaluation criteria in solid tumors(RECIST)v1.1 (CR:complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size(short axis\<10 mm),no new lesion;PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions,no new lesion) or modified revised assessment for neuro-oncology(RANO) for central nervous system malignancies (CR:disappearance of all target lesions,no new lesion;PR:\>=50% decrease in sum of products of 2 perpendicular diameters of target lesions, compared to baseline value,no new lesion);international neuroblastoma response criteria(INRC)for neuroblastoma also included minor response(MR)(Per protocol different criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow). OR rate:percentage of participants with BOR of CR or PR;CR or PR or MR.
Time frame: First dose of study treatment (Day 1) up to maximum of approximately 25 months
TSC: OR Rate Based on Investigator Assessment
OR: BOR of confirmed CR or PR or MR assessed by investigator per INRC for neuroblastoma. There were different criteria for CR and PR as specified in protocol for the following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow. Overall CR: All components met criteria for CR; PR: PR in at least 1 component and all other components were either CR, minimal disease (MD) \[bone marrow\], PR (soft tissue or bone) or not involved; no component with progressive disease (PD) and MR: PR or CR in at least one component but at least one other component with stable disease (SD); no component with PD. OR rate was presented as percentage of participants with BOR of CR or PR or MR.
Time frame: First dose of study treatment (Day 1) up to maximum of approximately 25 months
Phase 2: Event Free Survival (EFS) Based on Investigator Assessment
EFS: time from date of randomization to the date of first documentation of any of the following events based on investigator assessment: objective PD per RECIST v.1.1 (including PD without achieving a response or recurrence following a response), diagnosis of secondary malignancy, death due to any cause. PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Kaplan-Meier method was used for evaluation.
Time frame: From date of randomization up to objective PD, diagnosis of secondary malignancy or death, whichever occurred first (maximum of approximately 14 months)
Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Treatment Emergent AEs, Treatment Emergent SAEs, Treatment Related AEs, and Maximum Grade 3 or 4 and 5 AEs by CTCAE v4.03
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs: AEs that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect or other important medical event. Treatment-emergent AEs: AEs that occurred on or after the first dose of study treatment and up to 35 days after last dose of study treatment. AEs related to study drug as judged by the investigator were considered as treatment-related TEAEs. Severity of AEs were graded according to CTCAE version 4.03 as: Grade 3= severe, Grade 4= life threatening, and Grade 5= death related to AE.
Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Maximum CTCAE Grade in Hematology Parameters
Hematology parameters included activated partial thromboplastin time prolonged, anemia, hemoglobin increased, INR increased, lymphocyte count decreased and increased, neutrophil count decreased, platelet count decreased. Grades by CTCAE version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening and, Grade 5= death related to AE; Grade 0= non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter. Only those parameters are reported which had at least 1 participant for any reporting group.
Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Maximum CTCAE Grade in Chemistry Parameters
Clinical chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, GGT increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia and hypophosphatemia. According to CTCAE version 4.03: Grade 1=mild, Grade 2=moderate, Grade 3=severe and, Grade 4= life-threatening; Grade 0: non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter. Only those parameters are reported which had at least 1 participant for any reporting group.
Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Post-Baseline and Maximum Change From Baseline in ECG Parameters
ECG parameters included RR interval, PR interval, QRS complex, QT interval, QTc interval, QTcB interval and QTcF interval. In this outcome measure number of participants with post-baseline values and with maximum change from baseline values in ECG parameters are recorded.
Time frame: Baseline (pre-treatment) up to Cycle 3 (63 days)
Phase 1, Dose Escalation/Dose Determination Cohorts: Maximum Change From Baseline in Vital Signs Parameter- Blood Pressure
Blood pressure evaluation included SBP and DBP. SBP and DBP were measured in a supine position using an automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without any distractions.
Time frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 25 months)
Phase 1, Dose Escalation/Dose Determination Cohorts: Maximum Change From Baseline in Vital Signs Parameter- Pulse Rate
Pulse rate was measured in a supine position using an automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without any distractions.
Time frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 25 months)
Phase 1: Maximum Plasma Concentration (Cmax) at Steady-State of Palbociclib, TMZ, IRN, SN-38, CTX and TOPO
Cmax was observed directly from data. Active metabolite of IRN is 7-Ethyl-10-hydroxycamptothecin (SN-38). In this outcome measure, Cmax was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.
Time frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
Phase 1: Time to Reach Cmax (Tmax) of Palbociclib, TMZ, IRN SN-38, CTX and TOPO
Tmax was defined as time for Cmax. Active metabolite of IRN is SN-38. In this outcome measure, Tmax was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI. As pre-specified in protocol, time points in time frame could have a window of +/- 20% of the sampling time.
Time frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
Phase 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) of Palbociclib, TMZ, IRN SN-38, CTX and TOPO
Area under the concentration-time profile from time zero to the time tau. AUCtau was determined using the linear/log trapezoidal method. Active metabolite of IRN is SN-38. In this outcome measure, AUCtau was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.
Time frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
Phase 1: Pre-dose Plasma Concentration (Ctrough) at Steady-State of Palbociclib, TMZ, IRN SN-38, CTX and TOPO
Ctrough was defined as pre-dose plasma concentration during multiple dosing and observed directly from data. Active metabolite of IRN is SN-38. In this outcome measure, Ctrough was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D.
Time frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; IRN, SN-38, TOPO, CTX: PRD C1D2/D5, C2D5; TMZ Oral- PRD C1D5, C2D5 or TMZ IV- PRD C1D5, C2D5
Phase 1: Clearance of Palbociclib, TMZ, IRN SN-38, CTX and TOPO
Clearance of a drug is a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Active metabolite of IRN is SN-38. In this outcome measure, clearance was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. For IV administration CL/F was reported while for oral CL was reported. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.
Time frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; 2, 4, 6, 8 & 24 hrs PTD C1D5; IRN, SN-38, TOPO, CTX: PRD C1D2/D5, C2D5; PTI C1D5, C2D5; 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5, C2D5; 1, 4, 8 & 24 hrs PTD C1D5; 1 hr PTD C2D5 or TMZ IV- PRD, PTI C1D5, C2D5
Phase 1, Dose Escalation/Dose Determination Cohorts: OR Rate Based on Investigator Assessment
OR: BOR of confirmed CR or PR per RECIST v1.1 \[CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size(short axis\<10 mm), no new lesion;PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion\]or RANO for central nervous system malignancies\[CR: disappearance of all target lesions, no new lesion; PR:\>=50% decrease in sum of products of 2 perpendicular diameters of target lesions, compared to baseline value, no new lesion\]; INRC for neuroblastoma also included MR \[per protocol different criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow\]. OR rate: percentage of participants with BOR of CR or PR per RECIST or RANO; BOR of CR or PR or MR per INRC for neuroblastoma.
Time frame: First dose of study treatment (Day 1) up to maximum of approximately 25 months
Phase 1, Dose Escalation/Dose Determination Cohorts: Duration of Response (DOR) Based on Investigator Assessment
DOR was defined for participants with OR:time from the date of first documentation of OR to the date of first documentation of PD or death due to any cause. OR: BOR of confirmed CR or PR per RECIST v1.1\[CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size(short axis\<10 mm),no new lesion; PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion\] or RANO for central nervous system malignancies \[CR: disappearance of all target lesions, no new lesion; PR:\>=50% decrease in sum of products of 2 perpendicular diameters of target lesions, compared to baseline value, no new lesion\]; INRC for neuroblastoma also included MR \[per protocol different criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow\]. OR rate: % participants with BOR of CR or PR per RECIST or RANO; BOR of CR or PR or MR per INRC for neuroblastoma.
Time frame: From first documentation of OR to PD or death, whichever occurred earlier (maximum of approximately 25 months)
Phase 1, Dose Expansion Cohorts and TSC: DOR Based on Investigator Assessment
DOR for participants with OR: time from the date of first documentation of OR to the date of first documentation of PD or death due to any cause. OR: BOR of confirmed CR or PR per RECIST v1.1 \[CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis\<10 mm), no new lesion; PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion\] or RANO for central nervous system malignancies \[CR: disappearance of all target lesions, no new lesion; PR:\>=50% decrease in sum of products of 2 perpendicular diameters INRC for neuroblastoma also included MR \[per protocol different criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow\]. of target lesions, compared to baseline value, no new lesion\]; OR rate: % participants with BOR of CR or PR per RECIST or RANO; BOR of CR or PR or MR per INRC for neuroblastoma.
Time frame: From first documentation of OR to PD or death, whichever occurred earlier (maximum of approximately 25 months)
Phase 1, Dose Expansion Cohorts and TSC: Progression-Free Survival (PFS) Based on Investigator Assessment
PFS: time from date of first dose of study treatment to the date of the first documentation of objective PD or death due to any cause, whichever occurred first. Per RECIST, PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Per RANO, PD: \>=25% increase in the product of perpendicular diameters of any target lesion, taking as reference the smallest product; the appearance of one or more new lesions, worsening neurologic status not explained by causes unrelated to tumor progression; any increase in tumor cross-sectional area (tumor volume). Per INRC for neuroblastoma as specified in protocol different PD criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow; overall PD was when any component fulfilled criteria of PD. Kaplan-Meier method was used for evaluation.
Time frame: First dose of study treatment (Day 1) up to objective PD or death due to any cause, whichever occurred first (maximum of approximately 25 months)
Phase 1, Dose Expansion Cohorts and TSC: Overall Survival (OS)
OS: time from date of first dose of study treatment to the date of death due to any cause. Kaplan-Meier method was used for evaluation.
Time frame: First dose of study treatment (Day 1) up to death due to any cause (maximum of approximately 25 months)
Phase 2: Event-Free Survival (EFS) Based on Blinded Independent Review Committee (BIRC) Assessment
EFS: time from date of randomization to the date of first documentation of any of the following events based on investigator assessment: objective PD per RECIST v.1.1 (including PD without achieving a response or recurrence following a response), diagnosis of secondary malignancy, death due to any cause. PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Kaplan-Meier method was used for evaluation.
Time frame: First date of randomization to the date of first objective PD, diagnosis of secondary malignancy, death due to any cause (maximum of approximately 14 months)
Phase 2: OR Rate Based on Investigator Assessment
OR: BOR of CR or PR per RECIST v1.1. CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis\<10 mm), no new lesion; PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion. OR rate was percentage of participants with BOR of CR or PR.
Time frame: First dose of study treatment (Day 1) up to maximum of approximately 14 months
Phase 2: Comparison of Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) Assessment With Magnetic Resonance Imaging (MRI)/ Computed Tomography (CT) Assessment for OR
CR or PR per RECIST v1.1. CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis\<10 mm), no new lesion; PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion. PD per RECIST v.1.1 (including PD without achieving a response or recurrence following a response), diagnosis of secondary malignancy, death due to any cause. PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD= stable disease, NE= Not Evaluable.
Time frame: Cycle 4
Phase 2: PFS Based on Investigator Assessment
PFS: time from date of first dose of study treatment to the date of the first documentation of PD or death due to any cause. Per RECIST v1.1, PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Kaplan-Meier method was used for evaluation.
Time frame: First dose of study treatment (Day 1) up to PD or death due to any cause, whichever occurred (maximum of approximately 14 months)
Phase 2: OS
OS: time from date of first dose of study treatment to the date of death due to any cause. Kaplan-Meier method was used for evaluation.
Time frame: First dose of study treatment (Day 1) up to date of death due to any cause (maximum of approximately 76 months)
Phase 2: Number of Participants With Treatment Emergent AEs, Treatment Emergent SAEs, Treatment Related AEs, Treatment Related SAEs and AEs of Maximum Grade 3 or 4 and 5
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs: AEs that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect or other important medical event. Treatment-emergent AEs: AEs that occurred on or after the first dose of study treatment and up to 35 days after last dose of study treatment. AEs related to study drug as judged by the investigator were considered as treatment-related TEAEs. Severity of AEs were graded according to CTCAE version 4.03 as: Grade 3= severe, Grade 4= life threatening, and Grade 5= death related to AE.
Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 9.5 months)
Phase 2: Cmax at Steady-State of Palbociclib, TMZ, IRN and SN-38
Cmax was observed directly from data. Active metabolite of IRN is SN-38. In this outcome measure, Cmax was reported only for Phase 2 reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.
Time frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
Phase 2: Tmax of Palbociclib, TMZ, IRN and SN-38
Tmax was defined as time for Cmax. Active metabolite of IRN is SN-38. In this outcome measure, Tmax was reported only for Phase 2: reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.
Time frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
Phase 2: AUCtau,ss of Palbociclib, TMZ, IRN and SN-38
Area under the concentration-time profile from time zero to the time tau. AUCtau was determined using the linear/log trapezoidal method. Active metabolite of IRN is SN-38. In this outcome measure, AUCtau was reported for Phase 2 reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.
Time frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; 2, 4, 6, 8 & 24 hrs PTD C1D5; IRN, SN-38 : PRD C1D2/D5, C2D5; PTI C1D5, C2D5; 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5, C2D5; 1, 4, 8 & 24 hrs PTD C1D5; 1 hr PTD C2D5 or TMZ IV- PRD, PTI C1D5, C2D5
Phase 2: Ctrough at Steady-State of Palbociclib, TMZ, IRN and SN-38
Ctrough was defined as pre-dose plasma concentration during multiple dosing and observed directly from data. Active metabolite of IRN is SN-38. In this outcome measure, Ctrough was reported for Phase 2 reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D.
Time frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; IRN, SN-38 : PRD C1D2/D5, C2D5; TMZ Oral- PRD C1D5, C2D5; or TMZ IV- PRD C1D5, C2D5
Phase 2: Clearance of Palbociclib, TMZ, IRN and SN-38
Clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Active metabolite of IRN is SN-38. In this outcome measure, clearance was reported for Phase 2 reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. For IV administration CL/F was reported while for oral administration CL was reported. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.
Time frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; 2, 4, 6, 8 & 24 hrs PTD C1D5; IRN, SN-38 : PRD C1D2/D5, C2D5; PTI C1D5, C2D5; 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5, C2D5; 1, 4, 8 & 24 hrs PTD C1D5; 1 hr PTD C2D5 or TMZ IV- PRD, PTI C1D5, C2D5
Phase 2: Change From Baseline of Patient Reported Outcomes (PROMIS) Parent Proxy Profile v2.0 - Profile-25 Scale Score for Age >=5 to <=17 Years at Cycles 2 and 4
PROMIS Parent Proxy Profile V2.0 - Profile-25 instrument in this outcome measure was intended for parents serving as proxy reporters for their child (youth ages 5-17). The Profile-25 was a collection of short forms containing 4 items from six PROMIS domains (depressive symptoms, anxiety, physical function-mobility, pain interference, fatigue, and peer relationships with scores ranged from 20 to 80; where 20 = better health and 80 = worse health and for peer relationship 80 to 20; where 80 = better health and 20 = worse health along with a single item on pain intensity with 11 levels of responses from 0 (no pain) to 10 (worst pain you can think of).
Time frame: Baseline, Cycles 2 and 4
Phase 2: Change From Baseline of PROMIS Pediatric Profile v2.0 - Profile-25 Scale Score for Age >=8 to <=17 Years at Cycles 2 and 4
PROMIS Parent Proxy Profile V2.0 - Profile-25 instrument in this outcome measure was intended for parents serving as proxy reporters for their child (youth ages 5-17). The Profile-25 was a collection of short forms containing 4 items from six PROMIS domains (depressive symptoms, anxiety, physical function-mobility, pain interference, fatigue, and peer relationships with each item having 5 levels of responses (1=Never, 2=Almost never, 3=Sometimes, 4=Often, and 5=Almost always) along with a single item on pain intensity with 11 levels of responses from 0 (No pain) to 10 (Worst pain you can think of).
Time frame: Baseline, Cycles 2 and 4
Phase 2: Change From Baseline of PROMIS-29 Profile v2.1 Scale Score for Age >=18 Years at Cycles 2 and 4
PROMIS Profile-29 had eight domains (ability to participate in social roles, anxiety, depression, fatigue, pain Intensity, pain Interference, physical function, sleep disturbance). There were four items for each domain except pain intensity which had only 1 item. All items (except pain intensity) had a score of 1 to 5, when scores from each item was summed, it resulted to score ranged from 4 to 20, (except for pain intensity, where it is 1 to 10, highest score = worst pain), where for physical function highest score = without any difficulty and lowest score = unable to do; anxiety, depression, fatigue highest score = always and lowest score = never; sleep disturbance highest score = not at all, lowest score = very much; ability to participate in social roles and activities (trouble) highest score = never and lowest score = always; pain interference highest score = very much and lowest score = not at all.
Time frame: Baseline, Cycles 2 and 4
Phase 2: Average Days of Hospitalization
Hospitalization included planned and unplanned inpatient admissions regardless the reason.
Time frame: First dose of study treatment (Day 1) up to maximum of approximately 25 months
Phase 1 TSC: Number of Participants With Maximum CTCAE Grade in Chemistry Parameters - Upto Study Completion Date
Clinical chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia and hypophosphatemia. According to CTCAE version 4.03: Grade 1=mild, Grade 2=moderate, Grade 3=severe and Grade 4= life-threatening; Grade 0: non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter.
Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 24.2 months)
Phase 1 TSC: Number of Participants With Post-Baseline and Maximum Change From Baseline in ECG Parameters - Upto Study Completion Date
ECG parameters included PR interval, QRS interval, QT interval, Bazett's correction QT (QTcB) interval and Fridericia's correction (QTcF) interval. In this outcome measure number of participants with post-baseline values and with maximum change from baseline values in ECG parameters were recorded.
Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 24.2 months)
Phase 1 TSC: Maximum Change From Baseline in Vital Signs Parameter- Blood Pressure (Upto Study Completion Date)
Blood pressure evaluation included systolic blood pressure (SBP) and diastolic blood pressure (DBP). SBP and DBP were measured in a supine position using an automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without any distractions.
Time frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 24.2 months)
Phase 1, Dose Expansion Cohorts and TSC: Overall Survival (OS) - Upto Study Completion Date
OS: time from date of first dose of study treatment to the date of death due to any cause. Kaplan-Meier method was used for evaluation.
Time frame: First dose of study treatment (Day 1) up to death due to any cause (maximum of approximately 26 months)
Phase 2: OS - Upto Study Completion Date
OS: time from date of first dose of study treatment to the date of death due to any cause. Kaplan-Meier method was used for evaluation.
Time frame: First dose of study treatment (Day 1) up to date of death due to any cause (maximum up to 76 months of treatment exposure)
In this study there was: Phase 1- had dose escalation/determination cohorts followed by dose expansion cohorts and if eligibility as pre-specified in protocol was met then tumor-specific cohort (TSC) was conducted; Phase 2- compared the efficacy of palbociclib in combination with Irinotecan (IRN) and Temozolomide (TMZ) versus IRN and TMZ alone.
| Milestone | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|---|---|---|---|---|---|---|
| Started | 17 | 4 | 6 | 6 | 6 | 0 | 20 | 0 | 0 |
| Full analysis set (fas) | 17 | 4 | 6 | 6 | 6 | 0 | 20 | 0 | 0 |
| Safety analysis set (sas) | 17 | 4 | 6 | 6 | 6 | 0 | 20 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Not completed | 17 | 4 | 6 | 6 | 6 | 0 | 19 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Global deterioration of health status | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Progressive disease | 13 | 4 | 4 | 5 | 4 | 0 | 12 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|---|---|---|---|---|---|---|
| Started | 15 | 3 | 4 | 5 | 5 | 0 | 18 | 0 | 0 |
| Completed | 3 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 0 |
| Not completed | 12 | 3 | 4 | 3 | 4 | 0 | 17 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 12 | 2 | 4 | 2 | 3 | 0 | 13 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| Milestone | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 |
| Fas | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 |
| Sas | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Milestone | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 42 | 21 |
| Fas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 42 | 21 |
| Sas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41 | 21 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 42 | 21 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 31 | 12 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 2 |
| Milestone | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 37 | 21 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33 | 20 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 15 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
DLT was an adverse event (AE) occurring in the first cycle of treatment which were attributable to at least one of the agents in the combination that met the defined criteria of study per Sponsor. An AE we defined as any untoward medical occurrence in a study participant who received study drug without regard to possibility of causal relationship. AEs determined as DLT were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
| Participants | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|---|
| Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs) | 0 | 0 | 2 | 1 |
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs: AEs that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect or other important medical event. Treatment-emergent AEs: AEs that occurred on or after the first dose of study treatment and up to 35 days after last dose of study treatment. AEs related to study drug as judged by the investigator were considered as treatment-related TEAEs. Severity of AEs were graded according to CTCAE version 4.03 as: Grade 3= severe, Grade 4= life threatening, and Grade 5= death related to AE.
| Participants | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|
| Participants With Treatment emergent AEs | 17 | 20 | 7 |
| Participants With Treatment -emergent SAEs | 8 | 10 | 4 |
| Participants With Treatment Related AEs | 17 | 20 | 7 |
| Participants With Treatment Related SAEs | 3 | 8 | 2 |
| Participants With Maximum Grade 3 or 4 AEs | 14 | 19 | 7 |
| Participants With Maximum Grade 5 AEs | 1 | 0 | 0 |
Hematology parameters included activated partial thromboplastin time prolonged, anemia, hemoglobin increased, international normalized ratio (INR) increased, lymphocyte count decreased and increased, neutrophil count decreased, platelet count decreased. Grades by CTCAE version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening and Grade 5= death related to AE; Grade 0= non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter.
| Participants | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|
| Activated partial thromboplastin time prolonged — Grade 0 | 0 | — | — |
| Activated partial thromboplastin time prolonged — Grade 1 | 0 | — | — |
| Activated partial thromboplastin time prolonged — Grade 2 | 0 | — | — |
| Activated partial thromboplastin time prolonged — Grade 3 | 1 | — | — |
| Activated partial thromboplastin time prolonged — Grade 4 | NA | — | — |
| Anemia — Grade 0 | 0 | 0 | 0 |
| Anemia — Grade 1 | 6 | 0 | 0 |
| Anemia — Grade 2 | 5 | 5 | 1 |
| Anemia — Grade 3 | 6 | 15 | 6 |
| Anemia — Grade 4 | NA | NA | NA |
| Hemoglobin increased — Grade 0 | 14 | 19 | 7 |
| Hemoglobin increased — Grade 1 | 3 | 0 | 0 |
| Hemoglobin increased — Grade 2 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 3 | 0 | 1 | 0 |
| Hemoglobin increased — Grade 4 | NA | NA | NA |
| INR increased — Grade 0 | 1 | — | — |
| INR increased — Grade 1 | 0 | — | — |
| INR increased — Grade 2 | 0 | — | — |
| INR increased — Grade 3 | 0 | — | — |
| INR increased — Grade 4 | NA | — | — |
| Lymphocyte count decreased — Grade 0 | 3 | 0 | 0 |
| Lymphocyte count decreased — Grade 1 | 3 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 | 3 | 2 | 0 |
| Lymphocyte count decreased — Grade 3 | 8 | 7 | 2 |
| Lymphocyte count decreased — Grade 4 | 0 | 11 | 5 |
| Lymphocyte count increased — Grade 0 | 16 | 18 | 5 |
| Lymphocyte count increased — Grade 1 | NA | NA | NA |
| Lymphocyte count increased — Grade 2 | 1 | 2 | 0 |
| Lymphocyte count increased — Grade 3 | 0 | 0 | 2 |
| Lymphocyte count increased — Grade 4 | NA | NA | NA |
| Neutrophil count decreased — Grade 0 | 1 | 2 | 1 |
| Neutrophil count decreased — Grade 1 | 0 | 1 | 0 |
| Neutrophil count decreased — Grade 2 | 2 | 2 | 1 |
| Neutrophil count decreased — Grade 3 | 8 | 4 | 1 |
| Neutrophil count decreased — Grade 4 | 6 | 11 | 4 |
| Platelet count decreased — Grade 0 | 5 | 0 | 0 |
| Platelet count decreased — Grade 1 | 8 | 1 | 0 |
| Platelet count decreased — Grade 2 | 2 | 6 | 1 |
| Platelet count decreased — Grade 3 | 2 | 1 | 0 |
| Platelet count decreased — Grade 4 | 0 | 12 | 6 |
Clinical chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia and hypophosphatemia. According to CTCAE version 4.03: Grade 1=mild, Grade 2=moderate, Grade 3=severe and Grade 4= life-threatening; Grade 0: non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter.
| Participants | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|
| Alanine aminotransferase increased — Grade 0 | 13 | 15 | 2 |
| Alanine aminotransferase increased — Grade 1 | 1 | 3 | 4 |
| Alanine aminotransferase increased — Grade 2 | 1 | 1 | 0 |
| Alanine aminotransferase increased — Grade 3 | 2 | 1 | 1 |
| Alanine aminotransferase increased — Grade 4 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 0 | 12 | 13 | 5 |
| Alkaline phosphatase increased — Grade 1 | 3 | 6 | 2 |
| Alkaline phosphatase increased — Grade 2 | 2 | 1 | 0 |
| Alkaline phosphatase increased — Grade 3 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 4 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 0 | 13 | 15 | 1 |
| Aspartate aminotransferase increased — Grade 1 | 2 | 4 | 5 |
| Aspartate aminotransferase increased — Grade 2 | 0 | 1 | 1 |
| Aspartate aminotransferase increased — Grade 3 | 2 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 4 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 0 | 17 | 18 | 7 |
| Blood bilirubin increased — Grade 1 | 0 | 2 | 0 |
| Blood bilirubin increased — Grade 2 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 3 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 4 | 0 | 0 | 0 |
| Creatinine increased — Grade 0 | 1 | 1 | 1 |
| Creatinine increased — Grade 1 | 12 | 18 | 4 |
| Creatinine increased — Grade 2 | 3 | 1 | 2 |
| Creatinine increased — Grade 3 | 1 | 0 | 0 |
| Creatinine increased — Grade 4 | 0 | 0 | 0 |
| GGT increased — Grade 0 | 0 | — | 1 |
| GGT increased — Grade 1 | 0 | — | 0 |
| GGT increased — Grade 2 | 1 | — | 0 |
| GGT increased — Grade 3 | 0 | — | 0 |
| GGT increased — Grade 4 | 0 | — | 0 |
| Hypercalcemia — Grade 0 | 16 | 20 | 7 |
| Hypercalcemia — Grade 1 | 0 | 0 | 0 |
| Hypercalcemia — Grade 2 | 0 | 0 | 0 |
| Hypercalcemia — Grade 3 | 0 | 0 | 0 |
| Hypercalcemia — Grade 4 | 1 | 0 | 0 |
| Hyperglycemia — Grade 0 | 15 | 17 | 6 |
| Hyperglycemia — Grade 1 | 1 | 3 | 1 |
| Hyperglycemia — Grade 2 | 0 | 0 | 0 |
| Hyperglycemia — Grade 3 | 1 | 0 | 0 |
| Hyperglycemia — Grade 4 | 0 | 0 | 0 |
| Hyperkalemia — Grade 0 | 16 | 19 | 6 |
| Hyperkalemia — Grade 1 | 0 | 1 | 1 |
| Hyperkalemia — Grade 2 | 1 | 0 | 0 |
| Hyperkalemia — Grade 3 | 0 | 0 | 0 |
| Hyperkalemia — Grade 4 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 0 | 15 | 17 | 4 |
| Hypermagnesemia — Grade 1 | 2 | 2 | 3 |
| Hypermagnesemia — Grade 2 | NA | NA | NA |
| Hypermagnesemia — Grade 3 | 0 | 1 | 0 |
| Hypermagnesemia — Grade 4 | 0 | 0 | 0 |
| Hypernatremia — Grade 0 | 17 | 20 | 7 |
| Hypernatremia — Grade 1 | 0 | 0 | 0 |
| Hypernatremia — Grade 2 | 0 | 0 | 0 |
| Hypernatremia — Grade 3 | 0 | 0 | 0 |
| Hypernatremia — Grade 4 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 0 | 12 | 12 | 4 |
| Hypoalbuminemia — Grade 1 | 4 | 8 | 2 |
| Hypoalbuminemia — Grade 2 | 0 | 0 | 1 |
| Hypoalbuminemia — Grade 3 | 1 | 0 | 0 |
| Hypoalbuminemia — Grade 4 | NA | NA | NA |
| Hypocalcemia — Grade 0 | 15 | 17 | 3 |
| Hypocalcemia — Grade 1 | 2 | 3 | 4 |
| Hypocalcemia — Grade 2 | 0 | 0 | 0 |
| Hypocalcemia — Grade 3 | 0 | 0 | 0 |
| Hypocalcemia — Grade 4 | 0 | 0 | 0 |
| Hypoglycemia — Grade 0 | 15 | 18 | 7 |
| Hypoglycemia — Grade 1 | 1 | 2 | 0 |
| Hypoglycemia — Grade 2 | 0 | 0 | 0 |
| Hypoglycemia — Grade 3 | 1 | 0 | 0 |
| Hypoglycemia — Grade 4 | 0 | 0 | 0 |
| Hypokalemia — Grade 0 | 14 | 11 | 5 |
| Hypokalemia — Grade 1 | NA | NA | NA |
| Hypokalemia — Grade 2 | 3 | 9 | 1 |
| Hypokalemia — Grade 3 | 0 | 0 | 1 |
| Hypokalemia — Grade 4 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 0 | 14 | 14 | 7 |
| Hypomagnesemia — Grade 1 | 3 | 6 | 0 |
| Hypomagnesemia — Grade 2 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 3 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 4 | 0 | 0 | 0 |
| Hyponatremia — Grade 0 | 9 | 13 | 3 |
| Hyponatremia — Grade 1 | 8 | 7 | 4 |
| Hyponatremia — Grade 2 | NA | NA | NA |
| Hyponatremia — Grade 3 | 0 | 0 | 0 |
| Hyponatremia — Grade 4 | 0 | 0 | 0 |
| Hypophosphatemia — Grade 0 | 14 | 12 | 4 |
| Hypophosphatemia — Grade 1 | 2 | 4 | 3 |
| Hypophosphatemia — Grade 2 | 1 | 4 | 0 |
| Hypophosphatemia — Grade 3 | 0 | 0 | 0 |
| Hypophosphatemia — Grade 4 | 0 | 0 | 0 |
ECG parameters included PR interval, QRS complex, QT interval, Bazett's correction QT (QTcB) interval and Fridericia's correction (QTcF) interval. In this outcome measure number of participants with post-baseline values and with maximum change from baseline values in ECG parameters were recorded.
| Participants | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|
| PR Interval (milli second [msec]) Value greater than equal to (>=)300 | 0 | 0 | 0 |
| PR Interval (msec) %Change>=25% and Baseline > 200 | 0 | 0 | 0 |
| PR Interval (msec) %Change>=50% and Baseline <=200 | 0 | 0 | 0 |
| QRS Interval (msec) Value >=200 | 0 | 0 | 0 |
| QRS Interval (msec) %Change>=25% and Baseline >= 100 | 0 | 1 | 1 |
| QRS Interval (msec) %Change>=50% and Baseline < 100 | 1 | 1 | 0 |
| QT Interval (msec) Value less than equal to (<=)450 | 17 | 19 | 7 |
| QT Interval (msec) 450<Value<=480 | 0 | 0 | 0 |
| QT Interval (msec) 480<Value<=500 | 0 | 0 | 0 |
| QT Interval (msec) >500 | 0 | 1 | 0 |
| QT Interval (msec) Change<=30 | 6 | 16 | 3 |
| QT Interval (msec) 30<Change<=60 | 7 | 2 | 1 |
| QT Interval (msec) Change>60 | 4 | 2 | 0 |
| QTcB (msec) Value<=450 | 8 | 8 | 4 |
| QTcB (msec) 450<Value<=480 | 5 | 8 | 3 |
| QTcB (msec) 480<Value<=500 | 3 | 2 | 0 |
| QTcB (msec) Value>500 | 1 | 2 | 0 |
| QTcB (msec) Change<=30 | 12 | 13 | 2 |
| QTcB (msec) 30<Change<=60 | 5 | 5 | 2 |
| QTcB (msec) Change>60 | 0 | 2 | 0 |
| QTcF (msec) Value<=450 | 13 | 17 | 7 |
| QTcF (msec) 450<Value<=480 | 4 | 2 | 0 |
| QTcF (msec) 480<Value<=500 | 0 | 0 | 0 |
| QTcF (msec) Value>500 | 0 | 1 | 0 |
| QTcF (msec) Change<=30 | 11 | 15 | 2 |
| QTcF (msec) 30<Change<=60 | 6 | 4 | 2 |
| QTcF (msec) Change>60 | 0 | 1 | 0 |
Blood pressure evaluation included systolic blood pressure (SBP) and diastolic blood pressure (DBP). SBP and DBP were measured in the sitting position after participant had been in the supine position for approximately 2 minutes.
| millimeters of mercury | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|
| SBP | -3.2 ± 19.06 | 6.2 ± 16.13 | 5.4 ± 21.54 |
| DBP | -2.2 ± 16.83 | 4.2 ± 17.71 | -5.3 ± 13.66 |
Pulse rate was measured in a supine position using an automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without any distractions.
| Beats per minute | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|
| Phase 1, Dose Expansion Cohorts and TSC: Maximum Change From Baseline in Vital Signs Parameter- Pulse Rate | -7.0 ± 26.46 | 0.1 ± 29.5 | 1.0 ± 27.78 |
HbA1c is a form of hemoglobin which was measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Clinical significance was determined based on investigator
| Participants | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|
| Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Clinically Significant Changes in Glycosylated Hemoglobin (HbA1c) | 0 | 0 | 0 |
OR: best overall response(BOR) of confirmed complete response(CR) or partial response(PR) per response evaluation criteria in solid tumors(RECIST)v1.1 (CR:complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size(short axis\<10 mm),no new lesion;PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions,no new lesion) or modified revised assessment for neuro-oncology(RANO) for central nervous system malignancies (CR:disappearance of all target lesions,no new lesion;PR:\>=50% decrease in sum of products of 2 perpendicular diameters of target lesions, compared to baseline value,no new lesion);international neuroblastoma response criteria(INRC)for neuroblastoma also included minor response(MR)(Per protocol different criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow). OR rate:percentage of participants with BOR of CR or PR;CR or PR or MR.
| Percentage of Participants | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|
| Phase 1, Dose Expansion Cohorts: Objective Response (OR) Rate Based on Investigator Assessment | 11.8 (3.3 to 34.3) | 10.0 (2.8 to 30.1) |
OR: BOR of confirmed CR or PR or MR assessed by investigator per INRC for neuroblastoma. There were different criteria for CR and PR as specified in protocol for the following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow. Overall CR: All components met criteria for CR; PR: PR in at least 1 component and all other components were either CR, minimal disease (MD) \[bone marrow\], PR (soft tissue or bone) or not involved; no component with progressive disease (PD) and MR: PR or CR in at least one component but at least one other component with stable disease (SD); no component with PD. OR rate was presented as percentage of participants with BOR of CR or PR or MR.
| Percentage of Participants | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|
| TSC: OR Rate Based on Investigator Assessment | 28.6 (12.5 to 52.8) |
EFS: time from date of randomization to the date of first documentation of any of the following events based on investigator assessment: objective PD per RECIST v.1.1 (including PD without achieving a response or recurrence following a response), diagnosis of secondary malignancy, death due to any cause. PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Kaplan-Meier method was used for evaluation.
| Months | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|
| Phase 2: Event Free Survival (EFS) Based on Investigator Assessment | 1.54 (1.41 to 4.24) | 4.4 (2.6 to NA) |
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs: AEs that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect or other important medical event. Treatment-emergent AEs: AEs that occurred on or after the first dose of study treatment and up to 35 days after last dose of study treatment. AEs related to study drug as judged by the investigator were considered as treatment-related TEAEs. Severity of AEs were graded according to CTCAE version 4.03 as: Grade 3= severe, Grade 4= life threatening, and Grade 5= death related to AE.
| Participants | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|---|
| Participants With Treatment-emergent AEs | 4 | 6 | 6 | 6 |
| Participants With Treatment-emergent SAEs | 2 | 2 | 2 | 2 |
| Participants With Treatment Related AEs | 4 | 6 | 6 | 6 |
| Participants With Treatment Related SAEs | 1 | 1 | 2 | 2 |
| Participants With Maximum Grade 3 or 4 AEs | 4 | 4 | 6 | 6 |
| Participants With Maximum Grade 5 AEs | 0 | 0 | 0 | 0 |
Hematology parameters included activated partial thromboplastin time prolonged, anemia, hemoglobin increased, INR increased, lymphocyte count decreased and increased, neutrophil count decreased, platelet count decreased. Grades by CTCAE version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening and, Grade 5= death related to AE; Grade 0= non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter. Only those parameters are reported which had at least 1 participant for any reporting group.
| Participants | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|---|
| Anemia — Grade 0 | 0 | 1 | 1 | 0 |
| Anemia — Grade 1 | 3 | 2 | 3 | 0 |
| Anemia — Grade 2 | 1 | 3 | 1 | 2 |
| Anemia — Grade 3 | 0 | 0 | 1 | 4 |
| Anemia — Grade 4 | NA | NA | NA | NA |
| Hemoglobin increased — Grade 0 | 4 | 6 | 6 | 6 |
| Hemoglobin increased — Grade 1 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 2 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 3 | 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 4 | NA | NA | NA | NA |
| Lymphocyte count decreased — Grade 0 | 1 | 1 | 0 | 0 |
| Lymphocyte count decreased — Grade 1 | 0 | 2 | 2 | 0 |
| Lymphocyte count decreased — Grade 2 | 2 | 1 | 2 | 0 |
| Lymphocyte count decreased — Grade 3 | 1 | 2 | 2 | 3 |
| Lymphocyte count decreased — Grade 4 | 0 | 0 | 0 | 3 |
| Lymphocyte count increased — Grade 0 | 4 | 6 | 6 | 5 |
| Lymphocyte count increased — Grade 1 | NA | NA | NA | NA |
| Lymphocyte count increased — Grade 2 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 3 | 0 | 0 | 0 | 1 |
| Lymphocyte count increased — Grade 4 | NA | NA | NA | NA |
| Neutrophil count decreased — Grade 0 | 0 | 0 | 0 | 0 |
| Neutrophil count decreased — Grade 1 | 1 | 0 | 0 | 0 |
| Neutrophil count decreased — Grade 2 | 1 | 3 | 1 | 0 |
| Neutrophil count decreased — Grade 3 | 2 | 0 | 3 | 2 |
| Neutrophil count decreased — Grade 4 | 0 | 3 | 2 | 4 |
| Platelet count decreased — Grade 0 | 1 | 2 | 1 | 0 |
| Platelet count decreased — Grade 1 | 1 | 2 | 4 | 0 |
| Platelet count decreased — Grade 2 | 0 | 1 | 0 | 1 |
| Platelet count decreased — Grade 3 | 1 | 0 | 0 | 1 |
| Platelet count decreased — Grade 4 | 1 | 1 | 1 | 4 |
Clinical chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, GGT increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia and hypophosphatemia. According to CTCAE version 4.03: Grade 1=mild, Grade 2=moderate, Grade 3=severe and, Grade 4= life-threatening; Grade 0: non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter. Only those parameters are reported which had at least 1 participant for any reporting group.
| Participants | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|---|
| Alanine aminotransferase increased — Grade 0 | 2 | 3 | 4 | 3 |
| Alanine aminotransferase increased — Grade 1 | 1 | 2 | 2 | 3 |
| Alanine aminotransferase increased — Grade 2 | 1 | 1 | 0 | 0 |
| Alanine aminotransferase increased — Grade 3 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 4 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 0 | 3 | 5 | 6 | 3 |
| Alkaline phosphatase increased — Grade 1 | 0 | 1 | 0 | 3 |
| Alkaline phosphatase increased — Grade 2 | 1 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 3 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 4 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 0 | 0 | 4 | 4 | 4 |
| Aspartate aminotransferase increased — Grade 1 | 4 | 2 | 2 | 2 |
| Aspartate aminotransferase increased — Grade 2 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 3 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 4 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 0 | 4 | 6 | 6 | 5 |
| Blood bilirubin increased — Grade 1 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 2 | 0 | 0 | 0 | 1 |
| Blood bilirubin increased — Grade 3 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 4 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 0 | 0 | 0 | 0 | 2 |
| Creatinine increased — Grade 1 | 4 | 6 | 6 | 4 |
| Creatinine increased — Grade 2 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 3 | 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 4 | 0 | 0 | 0 | 0 |
| Hypercalcemia — Grade 0 | 4 | 6 | 6 | 5 |
| Hypercalcemia — Grade 1 | 0 | 0 | 0 | 1 |
| Hypercalcemia — Grade 2 | 0 | 0 | 0 | 0 |
| Hypercalcemia — Grade 3 | 0 | 0 | 0 | 0 |
| Hypercalcemia — Grade 4 | 0 | 0 | 0 | 0 |
| Hyperglycemia — Grade 0 | 4 | 6 | 6 | 6 |
| Hyperglycemia — Grade 1 | 0 | 0 | 0 | 0 |
| Hyperglycemia — Grade 2 | 0 | 0 | 0 | 0 |
| Hyperglycemia — Grade 3 | 0 | 0 | 0 | 0 |
| Hyperglycemia — Grade 4 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 0 | 4 | 6 | 6 | 6 |
| Hyperkalemia — Grade 1 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 2 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 3 | 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 4 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 0 | 4 | 4 | 5 | 4 |
| Hypermagnesemia — Grade 1 | 0 | 2 | 1 | 2 |
| Hypermagnesemia — Grade 2 | NA | NA | NA | NA |
| Hypermagnesemia — Grade 3 | 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 4 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 0 | 4 | 5 | 6 | 6 |
| Hypernatremia — Grade 1 | 0 | 1 | 0 | 0 |
| Hypernatremia — Grade 2 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 3 | 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 4 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 0 | 3 | 4 | 4 | 1 |
| Hypoalbuminemia — Grade 1 | 1 | 2 | 2 | 4 |
| Hypoalbuminemia — Grade 2 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 3 | 0 | 0 | 0 | 1 |
| Hypoalbuminemia — Grade 4 | NA | NA | NA | NA |
| Hypocalcemia — Grade 0 | 3 | 4 | 5 | 5 |
| Hypocalcemia — Grade 1 | 1 | 2 | 1 | 1 |
| Hypocalcemia — Grade 2 | 0 | 0 | 0 | 0 |
| Hypocalcemia — Grade 3 | 0 | 0 | 0 | 0 |
| Hypocalcemia — Grade 4 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 0 | 4 | 5 | 5 | 6 |
| Hypoglycemia — Grade 1 | 0 | 1 | 1 | 0 |
| Hypoglycemia — Grade 2 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 3 | 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 4 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 0 | 3 | 4 | 6 | 4 |
| Hypokalemia — Grade 1 | NA | NA | NA | NA |
| Hypokalemia — Grade 2 | 1 | 2 | 0 | 2 |
| Hypokalemia — Grade 3 | 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 4 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 0 | 4 | 6 | 6 | 4 |
| Hypomagnesemia — Grade 1 | 0 | 0 | 0 | 2 |
| Hypomagnesemia — Grade 2 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 3 | 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 4 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 0 | 3 | 6 | 6 | 3 |
| Hyponatremia — Grade 1 | 1 | 0 | 0 | 3 |
| Hyponatremia — Grade 2 | NA | NA | NA | NA |
| Hyponatremia — Grade 3 | 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 4 | 0 | 0 | 0 | 0 |
| Hypophosphatemia — Grade 0 | 4 | 5 | 5 | 4 |
| Hypophosphatemia — Grade 1 | 0 | 0 | 1 | 1 |
| Hypophosphatemia — Grade 2 | 0 | 1 | 0 | 1 |
| Hypophosphatemia — Grade 3 | 0 | 0 | 0 | 0 |
| Hypophosphatemia — Grade 4 | 0 | 0 | 0 | 0 |
ECG parameters included RR interval, PR interval, QRS complex, QT interval, QTc interval, QTcB interval and QTcF interval. In this outcome measure number of participants with post-baseline values and with maximum change from baseline values in ECG parameters are recorded.
| Participants | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|---|
| PR Interval (msec) Value >=300 | 0 | 0 | 0 | 0 |
| PR Interval (msec) % Change>=25% and Baseline > 200 | 0 | 0 | 0 | 0 |
| PR Interval (msec) % Change>=50% and Baseline <=200 | 0 | 0 | 0 | 0 |
| QRS Interval (msec) Value >=200 | 0 | 0 | 0 | 0 |
| QRS Interval (msec) %Change>=25% and Baseline >= 100 | 0 | 0 | 0 | 0 |
| QRS Interval (msec) %Change>=50% and Baseline < 100 | 0 | 0 | 0 | 0 |
| QT Interval (msec) Value <=450 | 4 | 6 | 6 | 6 |
| QT Interval (msec) 450<Value<=480 | 0 | 0 | 0 | 0 |
| QT Interval (msec) 480<Value<=500 | 0 | 0 | 0 | 0 |
| QT Interval (msec) >500 | 0 | 0 | 0 | 0 |
| QT Interval (msec) Change<=30 | 3 | 5 | 4 | 5 |
| QT Interval (msec) 30<Change<=60 | 0 | 1 | 2 | 1 |
| QT Interval (msec) Change>60 | 1 | 0 | 0 | 0 |
| QTcB (msec) Value<=450 | 0 | 4 | 4 | 2 |
| QTcB (msec) 450<Value<=480 | 4 | 1 | 2 | 3 |
| QTcB (msec) 480<Value<=500 | 0 | 0 | 0 | 0 |
| QTcB (msec) Value>500 | 0 | 0 | 0 | 1 |
| QTcB (msec) Change<=30 | 3 | 3 | 5 | 6 |
| QTcB (msec) 30<Change<=60 | 1 | 1 | 1 | 0 |
| QTcB (msec) Change>60 | 0 | 0 | 0 | 0 |
| QTcF (msec) Value<=450 | 4 | 5 | 6 | 4 |
| QTcF (msec) 450<Value<=480 | 0 | 0 | 0 | 1 |
| QTcF (msec) 480<Value<=500 | 0 | 0 | 0 | 1 |
| QTcF (msec) Value>500 | 0 | 0 | 0 | 0 |
| QTcF (msec) Change<=30 | 2 | 3 | 5 | 6 |
| QTcF (msec) 30<Change<=60 | 2 | 1 | 1 | 0 |
| QTcF (msec) Change>60 | 0 | 0 | 0 | 0 |
Blood pressure evaluation included SBP and DBP. SBP and DBP were measured in a supine position using an automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without any distractions.
| millimeters of mercury | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|---|
| SBP | -21.3 ± 9.88 | -10.0 ± 14.72 | 9.0 ± 21.64 | -5.0 ± 18.69 |
| DBP | -7.0 ± 10.98 | 0.3 ± 15.83 | -10.3 ± 15.49 | 1.2 ± 15.66 |
Pulse rate was measured in a supine position using an automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without any distractions.
| Beats per minute | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|---|
| Phase 1, Dose Escalation/Dose Determination Cohorts: Maximum Change From Baseline in Vital Signs Parameter- Pulse Rate | 8.5 ± 33.87 | 20.0 ± 30.19 | 12.7 ± 21.76 | 3.2 ± 42.97 |
Cmax was observed directly from data. Active metabolite of IRN is 7-Ethyl-10-hydroxycamptothecin (SN-38). In this outcome measure, Cmax was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.
| nanogram per milliliter (ng/mL) | Palbociclib 55 mg/m^2 + TMZ + IRN | Palbociclib 75 mg/m^2 + TMZ + IRN (Pooled) | Palbociclib 95 mg/m^2 + TMZ + IRN | Palbociclib 75 mg/m^2 + TOPO + CTX (Pooled) | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|---|---|
| Palbociclib | 80.44 ± 21 | 113.2 ± 49 | 127.9 ± 44 | 91.45 ± 58 | 81.31 ± 94 |
| IRN | 629.3 ± 10 | 595.5 ± 41 | 1033 ± 197 | — | — |
| SN-38 | 7.386 ± 103 | 8.746 ± 76 | 11.32 ± 69 | — | — |
| TMZ | 3930 ± 55 | 3960 ± 63 | 4404 ± 67 | — | — |
| TOPO | — | — | — | 25.52 ± 77 | 22.68 ± 57 |
| CTX | — | — | — | 14810 ± 40 | 15510 ± 51 |
Tmax was defined as time for Cmax. Active metabolite of IRN is SN-38. In this outcome measure, Tmax was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI. As pre-specified in protocol, time points in time frame could have a window of +/- 20% of the sampling time.
| Hours | Palbociclib 55 mg/m^2 + TMZ + IRN | Palbociclib 75 mg/m^2 + TMZ + IRN (Pooled) | Palbociclib 95 mg/m^2 + TMZ + IRN | Palbociclib 75 mg/m^2 + TOPO + CTX (Pooled) | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|---|---|
| Palbociclib | 6.03 (2.02 to 6.08) | 4.17 (1.85 to 6.47) | 5.02 (2.07 to 8.05) | 4.05 (1.97 to 24.0) | 4.0 (2.05 to 24.0) |
| IRN | 1.53 (1.5 to 1.62) | 1.58 (0.017 to 2.0) | 1.61 (1.53 to 1.78) | — | — |
| SN-38 | 2.64 (1.53 to 4.0) | 1.58 (0.017 to 6.02) | 1.61 (1.53 to 1.78) | — | — |
| TMZ | 1.12 (0.983 to 4.03) | 1.63 (0.95 to 4.08) | 2.84 (0.783 to 8.05) | — | — |
| TOPO | — | — | — | 0.567 (0.45 to 3.3) | 0.533 (0.5 to 0.783) |
| CTX | — | — | — | 0.617 (0.0 to 2.68) | 0.842 (0.533 to 1.98) |
Area under the concentration-time profile from time zero to the time tau. AUCtau was determined using the linear/log trapezoidal method. Active metabolite of IRN is SN-38. In this outcome measure, AUCtau was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.
| Hours*Nanogram per milliliter (hr*ng/mL) | Palbociclib 55 mg/m^2 + TMZ + IRN | Palbociclib 75 mg/m^2 + TMZ + IRN (Pooled) | Palbociclib 95 mg/m^2 + TMZ + IRN | Palbociclib 75 mg/m^2 + TOPO + CTX (Pooled) | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|---|---|
| Palbociclib | 1161 ± 7 | 1538 ± 49 | 2082 ± 38 | 1290 ± 59 | 1155 ± 102 |
| IRN | 3394 ± 28 | 2781 ± 44 | 4917 ± 111 | — | — |
| SN-38 | 69.46 ± 112 | 78.2 ± 130 | 98.28 ± 31 | — | — |
| TMZ | 18990 ± 29 | 16970 ± 58 | 26350 ± 40 | — | — |
| TOPO | — | — | — | 49.27 ± 52 | 40.25 ± 55 |
| CTX | — | — | — | 66260 ± 26 | 65340 ± 34 |
Ctrough was defined as pre-dose plasma concentration during multiple dosing and observed directly from data. Active metabolite of IRN is SN-38. In this outcome measure, Ctrough was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D.
| ng/mL | Palbociclib 55 mg/m^2 + TMZ + IRN | Palbociclib 75 mg/m^2 + TMZ + IRN (Pooled) | Palbociclib 95 mg/m^2 + TMZ + IRN | Palbociclib 75 mg/m^2 + TOPO + CTX (Pooled) | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|---|---|
| Palbociclib | 30.42 ± 7 | 36.01 ± 50 | 44.75 ± 54 | 23.98 ± 81 | 20.88 ± 76 |
| IRN | 18.1 ± 102 | 15.62 ± 56 | 16.21 ± 77 | — | — |
| SN-38 | 2.125 ± 3.0458 | 2.063 ± 2.731 | 1.123 ± 1.0186 | — | — |
| TMZ | 0.0 ± 0.0 | 0.0 ± 0.0 | 2.45 ± 6.0012 | — | — |
| TOPO | — | — | — | 0.0 ± 0.0 | 0.0 ± 0.0 |
| CTX | — | — | — | 232.8 ± 217 | 142.4 ± 136 |
Clearance of a drug is a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Active metabolite of IRN is SN-38. In this outcome measure, clearance was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. For IV administration CL/F was reported while for oral CL was reported. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.
| liter per hour (L/h) | Palbociclib 55 mg/m^2 + TMZ + IRN | Palbociclib 75 mg/m^2 + TMZ + IRN (Pooled) | Palbociclib 95 mg/m^2 + TMZ + IRN | Palbociclib 75 mg/m^2 + TOPO + CTX (Pooled) | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|---|---|
| Palbociclib | 62.07 ± 44 | 59.87 ± 88 | 63.47 ± 56 | 72.41 ± 59 | 52.69 ± 83 |
| IRN | 22.18 ± 29 | 22.62 ± 55 | 13.81 ± 83 | — | — |
| TMZ (Oral) | 7.884 ± 51 | 11.01 ± 84 | 6.459 ± 60 | — | — |
| TMZ (IV) | — | 2.935 ± 53 | 2.38 | — | — |
| TOPO | — | — | — | 18.35 ± 68 | 15.63 ± 59 |
| CTX | — | — | — | 4.731 ± 43 | 3.098 ± 16 |
OR: BOR of confirmed CR or PR per RECIST v1.1 \[CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size(short axis\<10 mm), no new lesion;PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion\]or RANO for central nervous system malignancies\[CR: disappearance of all target lesions, no new lesion; PR:\>=50% decrease in sum of products of 2 perpendicular diameters of target lesions, compared to baseline value, no new lesion\]; INRC for neuroblastoma also included MR \[per protocol different criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow\]. OR rate: percentage of participants with BOR of CR or PR per RECIST or RANO; BOR of CR or PR or MR per INRC for neuroblastoma.
| Percentage of Participants | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|---|
| Phase 1, Dose Escalation/Dose Determination Cohorts: OR Rate Based on Investigator Assessment | 0 (0.0 to 49.0) | 0 (0.0 to 39.0) | 0 (0.0 to 39.0) | 16.7 (3.0 to 56.4) |
DOR was defined for participants with OR:time from the date of first documentation of OR to the date of first documentation of PD or death due to any cause. OR: BOR of confirmed CR or PR per RECIST v1.1\[CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size(short axis\<10 mm),no new lesion; PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion\] or RANO for central nervous system malignancies \[CR: disappearance of all target lesions, no new lesion; PR:\>=50% decrease in sum of products of 2 perpendicular diameters of target lesions, compared to baseline value, no new lesion\]; INRC for neuroblastoma also included MR \[per protocol different criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow\]. OR rate: % participants with BOR of CR or PR per RECIST or RANO; BOR of CR or PR or MR per INRC for neuroblastoma.
| Months | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|---|
| Phase 1, Dose Escalation/Dose Determination Cohorts: Duration of Response (DOR) Based on Investigator Assessment | — | — | — | NA |
DOR for participants with OR: time from the date of first documentation of OR to the date of first documentation of PD or death due to any cause. OR: BOR of confirmed CR or PR per RECIST v1.1 \[CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis\<10 mm), no new lesion; PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion\] or RANO for central nervous system malignancies \[CR: disappearance of all target lesions, no new lesion; PR:\>=50% decrease in sum of products of 2 perpendicular diameters INRC for neuroblastoma also included MR \[per protocol different criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow\]. of target lesions, compared to baseline value, no new lesion\]; OR rate: % participants with BOR of CR or PR per RECIST or RANO; BOR of CR or PR or MR per INRC for neuroblastoma.
| Months | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | Tumor-Specific Cohort (TSC): Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|
| Phase 1, Dose Expansion Cohorts and TSC: DOR Based on Investigator Assessment | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
PFS: time from date of first dose of study treatment to the date of the first documentation of objective PD or death due to any cause, whichever occurred first. Per RECIST, PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Per RANO, PD: \>=25% increase in the product of perpendicular diameters of any target lesion, taking as reference the smallest product; the appearance of one or more new lesions, worsening neurologic status not explained by causes unrelated to tumor progression; any increase in tumor cross-sectional area (tumor volume). Per INRC for neuroblastoma as specified in protocol different PD criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow; overall PD was when any component fulfilled criteria of PD. Kaplan-Meier method was used for evaluation.
| Months | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | Tumor-Specific Cohort (TSC): Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|
| Phase 1, Dose Expansion Cohorts and TSC: Progression-Free Survival (PFS) Based on Investigator Assessment | 1.54 (1.41 to 2.92) | 4.04 (1.25 to 8.44) | 1.97 (1.08 to NA) |
OS: time from date of first dose of study treatment to the date of death due to any cause. Kaplan-Meier method was used for evaluation.
| Months | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | Tumor-Specific Cohort (TSC): Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|
| Phase 1, Dose Expansion Cohorts and TSC: Overall Survival (OS) | 7.62 (4.27 to 14.59) | 7.46 (4.6 to 8.64) | NA (NA to NA) |
EFS: time from date of randomization to the date of first documentation of any of the following events based on investigator assessment: objective PD per RECIST v.1.1 (including PD without achieving a response or recurrence following a response), diagnosis of secondary malignancy, death due to any cause. PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Kaplan-Meier method was used for evaluation.
| Months | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|
| Phase 2: Event-Free Survival (EFS) Based on Blinded Independent Review Committee (BIRC) Assessment | 1.54 (1.35 to 3.22) | 4.14 (1.38 to 9.13) |
OR: BOR of CR or PR per RECIST v1.1. CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis\<10 mm), no new lesion; PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion. OR rate was percentage of participants with BOR of CR or PR.
| Percentage of Participants | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|
| Phase 2: OR Rate Based on Investigator Assessment | 14.3 (6.3 to 29.4) | 15.8 (5.5 to 37.6) |
CR or PR per RECIST v1.1. CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis\<10 mm), no new lesion; PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion. PD per RECIST v.1.1 (including PD without achieving a response or recurrence following a response), diagnosis of secondary malignancy, death due to any cause. PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD= stable disease, NE= Not Evaluable.
| Participants | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|
| CR per FDG-PET | 0 | 0 |
| CR per MRI/CT | 0 | 0 |
| PR per FDG-PET | 2 | 3 |
| PR per MRI/CT | 1 | 2 |
| PD per FDG-PET | 3 | 3 |
| PD per MRI/CT | 1 | 1 |
| SD per FDG-PET | 3 | 0 |
| SD per MRI/CT | 6 | 5 |
| NE per FDG-PET | 0 | 2 |
| NE per MRI/CT | 0 | 0 |
PFS: time from date of first dose of study treatment to the date of the first documentation of PD or death due to any cause. Per RECIST v1.1, PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Kaplan-Meier method was used for evaluation.
| Months | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|
| Phase 2: PFS Based on Investigator Assessment | 1.54 (1.41 to 4.24) | 4.4 (2.6 to NA) |
OS: time from date of first dose of study treatment to the date of death due to any cause. Kaplan-Meier method was used for evaluation.
| Months | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|
| Phase 2: OS | 10.64 (8.44 to 20.83) | 11.43 (7.46 to 19.02) |
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs: AEs that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect or other important medical event. Treatment-emergent AEs: AEs that occurred on or after the first dose of study treatment and up to 35 days after last dose of study treatment. AEs related to study drug as judged by the investigator were considered as treatment-related TEAEs. Severity of AEs were graded according to CTCAE version 4.03 as: Grade 3= severe, Grade 4= life threatening, and Grade 5= death related to AE.
| Participants | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|
| Participants With Treatment emergent AEs | 38 | 20 |
| Participants With Treatment -emergent SAEs | 15 | 4 |
| Participants With Treatment Related AEs | 36 | 19 |
| Participants With Treatment Related SAEs | 7 | 3 |
| Participants With Maximum Grade 3 or 4 AEs | 34 | 17 |
| Participants With Maximum Grade 5 AEs | 1 | 0 |
Cmax was observed directly from data. Active metabolite of IRN is SN-38. In this outcome measure, Cmax was reported only for Phase 2 reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.
| ng/mL | Palbociclib 75 mg/m^2 + IRN + TMZ |
|---|---|
| Palbociclib | 114.4 ± 49 |
| IRN | 709.9 ± 72 |
| SN-38 | 8.527 ± 61 |
| TMZ | 3457 ± 75 |
Tmax was defined as time for Cmax. Active metabolite of IRN is SN-38. In this outcome measure, Tmax was reported only for Phase 2: reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.
| Hours | Palbociclib 75 mg/m^2 + IRN + TMZ |
|---|---|
| Palbociclib | 4.0 (1.68 to 8.0) |
| IRN | 1.57 (1.42 to 4.02) |
| SN-38 | 1.58 (1.42 to 6.83) |
| TMZ | 1.11 (0.667 to 4.13) |
Area under the concentration-time profile from time zero to the time tau. AUCtau was determined using the linear/log trapezoidal method. Active metabolite of IRN is SN-38. In this outcome measure, AUCtau was reported for Phase 2 reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.
| hr*ng/mL | Palbociclib 75 mg/m^2 + IRN + TMZ |
|---|---|
| Palbociclib | 1525 ± 38 |
| IRN | 2773 ± 28 |
| SN-38 | 69.83 ± 77 |
| TMZ | 19470 ± 31 |
Ctrough was defined as pre-dose plasma concentration during multiple dosing and observed directly from data. Active metabolite of IRN is SN-38. In this outcome measure, Ctrough was reported for Phase 2 reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D.
| ng/mL | Palbociclib 75 mg/m^2 + IRN + TMZ |
|---|---|
| Palbociclib | 26.09 ± 80 |
| IRN | 14.25 ± 57 |
| SN-38 | 1.434 ± 1.91 |
| TMZ | 0.0 ± 0.0 |
Clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Active metabolite of IRN is SN-38. In this outcome measure, clearance was reported for Phase 2 reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. For IV administration CL/F was reported while for oral administration CL was reported. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.
| L/h | Palbociclib 75 mg/m^2 + IRN + TMZ |
|---|---|
| Palbociclib | 63.65 ± 53 |
| IRN | 23.43 ± 45 |
| TMZ (IV) | 6.843 ± 49 |
| TMZ (Oral) | 4.97 |
PROMIS Parent Proxy Profile V2.0 - Profile-25 instrument in this outcome measure was intended for parents serving as proxy reporters for their child (youth ages 5-17). The Profile-25 was a collection of short forms containing 4 items from six PROMIS domains (depressive symptoms, anxiety, physical function-mobility, pain interference, fatigue, and peer relationships with scores ranged from 20 to 80; where 20 = better health and 80 = worse health and for peer relationship 80 to 20; where 80 = better health and 20 = worse health along with a single item on pain intensity with 11 levels of responses from 0 (no pain) to 10 (worst pain you can think of).
| Scores on a Scale | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|
| Anxiety Raw Summed Score Cycle 2 | -0.2 ± 3.19 | -3.3 ± 3.77 |
| Anxiety Raw Summed Score Cycle 4 | -1.0 ± 2.58 | -4.0 ± 3.61 |
| Depressive Symptoms Raw Summed Score Cycle 2 | 0.0 ± 2.0 | -1.3 ± 3.5 |
| Depressive Symptoms Raw Summed Score Cycle 4 | 0.0 ± 2.45 | -1.0 ± 5.0 |
| Fatigue Raw Summed Score Cycle 2 | 0.2 ± 4.12 | -2.8 ± 2.22 |
| Fatigue Raw Summed Score Cycle 4 | 2.3 ± 4.27 | -3.0 ± 2.65 |
| Pain Intensity Raw Summed Score Cycle 2 | -0.5 ± 3.51 | -3.8 ± 2.87 |
| Pain Intensity Raw Summed Score Cycle 4 | 2.0 ± 4.16 | -3.3 ± 3.06 |
| Pain Interference Raw Summed Score Cycle 2 | -2.5 ± 5.68 | -6.0 ± 5.48 |
| Pain Interference Raw Summed Score Cycle 4 | 0.5 ± 8.74 | -4.7 ± 2.89 |
| Peer Relationships Raw Summed Score Cycle 2 | -1.0 ± 4.1 | 1.5 ± 4.43 |
| Peer Relationships Raw Summed Score Cycle 4 | -1.0 ± 3.74 | 0.3 ± 7.51 |
| Physical Function Mobility Raw Summed Score Cycle 2 | -1.8 ± 1.83 | 4.5 ± 2.65 |
| Physical Function Mobility Raw Summed Score Cycle 4 | -2.3 ± 3.77 | 7.3 ± 3.06 |
PROMIS Parent Proxy Profile V2.0 - Profile-25 instrument in this outcome measure was intended for parents serving as proxy reporters for their child (youth ages 5-17). The Profile-25 was a collection of short forms containing 4 items from six PROMIS domains (depressive symptoms, anxiety, physical function-mobility, pain interference, fatigue, and peer relationships with each item having 5 levels of responses (1=Never, 2=Almost never, 3=Sometimes, 4=Often, and 5=Almost always) along with a single item on pain intensity with 11 levels of responses from 0 (No pain) to 10 (Worst pain you can think of).
| Scores on a Scale | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|
| Anxiety Raw Summed Score Cycle 2 | 0.2 ± 2.71 | -1.5 ± 4.09 |
| Anxiety Raw Summed Score Cycle 4 | 0.8 ± 2.5 | -1.8 ± 2.17 |
| Depressive Symptoms Raw Summed Score Cycle 2 | -0.8 ± 1.72 | -1.8 ± 1.92 |
| Depressive Symptoms Raw Summed Score Cycle 4 | 1.0 ± 2.94 | -2.4 ± 2.07 |
| Fatigue Raw Summed Score Cycle 2 | 0.3 ± 3.01 | -1.5 ± 0.84 |
| Fatigue Raw Summed Score Cycle 4 | 2.8 ± 2.63 | -1.8 ± 0.84 |
| Pain Intensity Raw Summed Score Cycle 2 | -0.3 ± 2.94 | -2.5 ± 3.83 |
| Pain Intensity Raw Summed Score Cycle 4 | 1.8 ± 2.22 | -2.6 ± 3.65 |
| Pain Interference Raw Summed Score Cycle 2 | 1.5 ± 6.12 | -3.7 ± 7.99 |
| Pain Interference Raw Summed Score Cycle 4 | 5.8 ± 4.57 | -4.8 ± 5.59 |
| Peer Relationships Raw Summed Score Cycle 2 | 1.5 ± 1.52 | 1.8 ± 3.25 |
| Peer Relationships Raw Summed Score Cycle 4 | 1.0 ± 3.74 | 1.0 ± 1.41 |
| Physical Function Mobility Raw Summed Score Cycle 2 | -1.2 ± 0.98 | 1.7 ± 2.58 |
| Physical Function Mobility Raw Summed Score Cycle 4 | -3.3 ± 2.87 | 1.8 ± 3.7 |
PROMIS Profile-29 had eight domains (ability to participate in social roles, anxiety, depression, fatigue, pain Intensity, pain Interference, physical function, sleep disturbance). There were four items for each domain except pain intensity which had only 1 item. All items (except pain intensity) had a score of 1 to 5, when scores from each item was summed, it resulted to score ranged from 4 to 20, (except for pain intensity, where it is 1 to 10, highest score = worst pain), where for physical function highest score = without any difficulty and lowest score = unable to do; anxiety, depression, fatigue highest score = always and lowest score = never; sleep disturbance highest score = not at all, lowest score = very much; ability to participate in social roles and activities (trouble) highest score = never and lowest score = always; pain interference highest score = very much and lowest score = not at all.
| Scores on a Scale | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|
| Ability to Participate in Social Roles Raw Summed Score Cycle 2 | 3.0 ± 4.24 | -2.0 |
| Ability to Participate in Social Roles Raw Summed Score Cycle 4 | -3.0 | -2.0 |
| Anxiety Raw Summed Score Cycle 2 | -2.0 ± 1.41 | 0.0 |
| Anxiety Raw Summed Score Cycle 4 | -3.0 | 0.0 |
| Depression Raw Summed Score Cycle 2 | -1.5 ± 2.12 | 0.0 |
| Depression Raw Summed Score Cycle 4 | 0.0 | 2.0 |
| Fatigue Raw Summed Score Cycle 2 | -5.5 ± 4.95 | 5.0 |
| Fatigue Raw Summed Score Cycle 4 | -3.0 | 8.0 |
| Pain Intensity Raw Summed Score Cycle 2 | -0.5 ± 2.12 | -1.0 |
| Pain Intensity Raw Summed Score Cycle 4 | -1.0 | -1.0 |
| Pain Interference Raw Summed Score Cycle 2 | -1.0 ± 1.41 | 1.0 |
| Pain Interference Raw Summed Score Cycle 4 | 0.0 | 1.0 |
| Physical Function Raw Summed Score Cycle 2 | 1.0 ± 1.41 | -8.0 |
| Physical Function Raw Summed Score Cycle 4 | — | -4.0 |
| Sleep Disturbance Raw Summed Score Cycle 2 | 1.0 ± 1.41 | 2.0 |
| Sleep Disturbance Raw Summed Score Cycle 4 | -4.0 | 3.0 |
Hospitalization included planned and unplanned inpatient admissions regardless the reason.
| Days | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|
| Phase 2: Average Days of Hospitalization | 3.5 ± 6.804 | 1.26 ± 0.525 |
Clinical chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia and hypophosphatemia. According to CTCAE version 4.03: Grade 1=mild, Grade 2=moderate, Grade 3=severe and Grade 4= life-threatening; Grade 0: non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter.
| Participants | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|
| Alanine aminotransferase increased — Grade 0 | 2 |
| Alanine aminotransferase increased — Grade 1 | 4 |
| Alanine aminotransferase increased — Grade 2 | 0 |
| Alanine aminotransferase increased — Grade 3 | 1 |
| Alanine aminotransferase increased — Grade 4 | 0 |
| Alkaline phosphatase increased — Grade 0 | 5 |
| Alkaline phosphatase increased — Grade 1 | 2 |
| Alkaline phosphatase increased — Grade 2 | 0 |
| Alkaline phosphatase increased — Grade 3 | 0 |
| Alkaline phosphatase increased — Grade 4 | 0 |
| Aspartate aminotransferase increased — Grade 0 | 1 |
| Aspartate aminotransferase increased — Grade 1 | 5 |
| Aspartate aminotransferase increased — Grade 2 | 1 |
| Aspartate aminotransferase increased — Grade 3 | 0 |
| Aspartate aminotransferase increased — Grade 4 | 0 |
| Blood bilirubin increased — Grade 0 | 6 |
| Blood bilirubin increased — Grade 1 | 1 |
| Blood bilirubin increased — Grade 2 | 0 |
| Blood bilirubin increased — Grade 3 | 0 |
| Blood bilirubin increased — Grade 4 | 0 |
| Creatinine increased — Grade 0 | 1 |
| Creatinine increased — Grade 1 | 4 |
| Creatinine increased — Grade 2 | 2 |
| Creatinine increased — Grade 3 | 0 |
| Creatinine increased — Grade 4 | 0 |
| GGT increased — Grade 0 | 1 |
| GGT increased — Grade 1 | 0 |
| GGT increased — Grade 2 | 0 |
| GGT increased — Grade 3 | 0 |
| GGT increased — Grade 4 | 0 |
| Hypercalcemia — Grade 0 | 7 |
| Hypercalcemia — Grade 1 | 0 |
| Hypercalcemia — Grade 2 | 0 |
| Hypercalcemia — Grade 3 | 0 |
| Hypercalcemia — Grade 4 | 0 |
| Hyperglycemia — Grade 0 | 6 |
| Hyperglycemia — Grade 1 | 1 |
| Hyperglycemia — Grade 2 | 0 |
| Hyperglycemia — Grade 3 | 0 |
| Hyperglycemia — Grade 4 | 0 |
| Hyperkalemia — Grade 0 | 6 |
| Hyperkalemia — Grade 1 | 1 |
| Hyperkalemia — Grade 2 | 0 |
| Hyperkalemia — Grade 3 | 0 |
| Hyperkalemia — Grade 4 | 0 |
| Hypermagnesemia — Grade 0 | 3 |
| Hypermagnesemia — Grade 1 | 3 |
| Hypermagnesemia — Grade 2 | NA |
| Hypermagnesemia — Grade 3 | 0 |
| Hypermagnesemia — Grade 4 | 1 |
| Hypernatremia — Grade 0 | 7 |
| Hypernatremia — Grade 1 | 0 |
| Hypernatremia — Grade 2 | 0 |
| Hypernatremia — Grade 3 | 0 |
| Hypernatremia — Grade 4 | 0 |
| Hypoalbuminemia — Grade 0 | 4 |
| Hypoalbuminemia — Grade 1 | 2 |
| Hypoalbuminemia — Grade 2 | 1 |
| Hypoalbuminemia — Grade 3 | 0 |
| Hypoalbuminemia — Grade 4 | NA |
| Hypocalcemia — Grade 0 | 3 |
| Hypocalcemia — Grade 1 | 4 |
| Hypocalcemia — Grade 2 | 0 |
| Hypocalcemia — Grade 3 | 0 |
| Hypocalcemia — Grade 4 | 0 |
| Hypoglycemia — Grade 0 | 6 |
| Hypoglycemia — Grade 1 | 0 |
| Hypoglycemia — Grade 2 | 0 |
| Hypoglycemia — Grade 3 | 0 |
| Hypoglycemia — Grade 4 | 1 |
| Hypokalemia — Grade 0 | 5 |
| Hypokalemia — Grade 1 | NA |
| Hypokalemia — Grade 2 | 1 |
| Hypokalemia — Grade 3 | 1 |
| Hypokalemia — Grade 4 | 0 |
| Hypomagnesemia — Grade 0 | 6 |
| Hypomagnesemia — Grade 1 | 1 |
| Hypomagnesemia — Grade 2 | 0 |
| Hypomagnesemia — Grade 3 | 0 |
| Hypomagnesemia — Grade 4 | 0 |
| Hyponatremia — Grade 0 | 3 |
| Hyponatremia — Grade 1 | 4 |
| Hyponatremia — Grade 2 | NA |
| Hyponatremia — Grade 3 | 0 |
| Hyponatremia — Grade 4 | 0 |
| Hypophosphatemia — Grade 0 | 4 |
| Hypophosphatemia — Grade 1 | 3 |
| Hypophosphatemia — Grade 2 | 0 |
| Hypophosphatemia — Grade 3 | 0 |
| Hypophosphatemia — Grade 4 | 0 |
ECG parameters included PR interval, QRS interval, QT interval, Bazett's correction QT (QTcB) interval and Fridericia's correction (QTcF) interval. In this outcome measure number of participants with post-baseline values and with maximum change from baseline values in ECG parameters were recorded.
| Participants | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|
| PR Interval (millisecond [msec]) Value greater than equal to (>=)300 | 0 |
| PR Interval (msec) %Change>=25% and Baseline > 200 | 0 |
| PR Interval (msec) %Change>=50% and Baseline <=200 | 0 |
| QRS Interval (msec) Value >=200 | 0 |
| QRS Interval (msec) %Change>=25% and Baseline >= 100 | 1 |
| QRS Interval (msec) %Change>=50% and Baseline < 100 | 0 |
| QT Interval (msec) Value less than equal to (<=)450 | 7 |
| QT Interval (msec) 450<Value<=480 | 0 |
| QT Interval (msec) 480<Value<=500 | 0 |
| QT Interval (msec) >500 | 0 |
| QT Interval (msec) Change<=30 | 3 |
| QT Interval (msec) 30<Change<=60 | 1 |
| QT Interval (msec) Change>60 | 0 |
| QTcB (msec) Value<=450 | 4 |
| QTcB (msec) 450<Value<=480 | 3 |
| QTcB (msec) 480<Value<=500 | 0 |
| QTcB (msec) Value>500 | 0 |
| QTcB (msec) Change<=30 | 3 |
| QTcB (msec) 30<Change<=60 | 1 |
| QTcB (msec) Change>60 | 0 |
| QTcF (msec) Value<=450 | 7 |
| QTcF (msec) 450<Value<=480 | 0 |
| QTcF (msec) 480<Value<=500 | 0 |
| QTcF (msec) Value>500 | 0 |
| QTcF (msec) Change<=30 | 2 |
| QTcF (msec) 30<Change<=60 | 2 |
| QTcF (msec) Change>60 | 0 |
Blood pressure evaluation included systolic blood pressure (SBP) and diastolic blood pressure (DBP). SBP and DBP were measured in a supine position using an automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without any distractions.
| millimeters of mercury | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|
| SBP | 5.4 ± 21.54 |
| DBP | -9.3 ± 11.71 |
OS: time from date of first dose of study treatment to the date of death due to any cause. Kaplan-Meier method was used for evaluation.
| Months | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | Tumor-Specific Cohort (TSC): Palbociclib 75 mg/m^2 + TOPO + CTX |
|---|---|---|---|
| Phase 1, Dose Expansion Cohorts and TSC: Overall Survival (OS) - Upto Study Completion Date | 13.04 (4.67 to 25.3) | 8.54 (7.39 to 19.71) | NA (NA to NA) |
OS: time from date of first dose of study treatment to the date of death due to any cause. Kaplan-Meier method was used for evaluation.
| Months | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|
| Phase 2: OS - Upto Study Completion Date | 10.68 (8.44 to 20.9) | 11.43 (7.46 to 19.84) |
Collected over Phase 1 and TSC: AEs and all-cause mortality: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 and 24.2 months respectively respectively); Phase 2: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 76 months); All-cause mortality: up to approximately 14 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | 3/6 (50%) | 2/6 (33.3%) | 6/6 (100%) |
| Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | 12/17 (70.6%) | 8/17 (47.1%) | 17/17 (100%) |
| Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | 2/4 (50%) | 2/4 (50%) | 4/4 (100%) |
| Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | 5/6 (83.3%) | 2/6 (33.3%) | 6/6 (100%) |
| Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | 3/6 (50%) | 2/6 (33.3%) | 6/6 (100%) |
| Phase 1, Dose Escalation Cohort 2 + Dose Expansion: Palbociclib 75 mg/m^2 + TMZ + IRN | 15/23 (65.2%) | 10/23 (43.5%) | 23/23 (100%) |
| Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | 14/20 (70%) | 10/20 (50%) | 20/20 (100%) |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX | 2/7 (28.6%) | 4/7 (57.1%) | 7/7 (100%) |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | 26/41 (63.4%) | 15/41 (36.6%) | 37/41 (90.2%) |
| Phase 2: IRN + TMZ | 15/21 (71.4%) | 4/21 (19%) | 20/21 (95.2%) |
| Event | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | Phase 1, Dose Escalation Cohort 2 + Dose Expansion: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/6 | 1/17 | 0/4 | 0/6 | 1/6 | 2/23 | 6/20 | 1/7 | 4/41 | 0/21 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 0/17 | 1/4 | 0/6 | 0/6 | 0/23 | 0/20 | 0/7 | 0/41 | 0/21 |
| ShockVascular disorders | 0/6 | 0/17 | 1/4 | 0/6 | 0/6 | 0/23 | 0/20 | 0/7 | 0/41 | 0/21 |
| Atrial fibrillationCardiac disorders | 1/6 | 0/17 | 0/4 | 0/6 | 0/6 | 1/23 | 0/20 | 0/7 | 0/41 | 0/21 |
| Pericardial effusionCardiac disorders | 1/6 | 0/17 | 0/4 | 0/6 | 0/6 | 1/23 | 0/20 | 0/7 | 0/41 | 0/21 |
| Chest painGeneral disorders | 1/6 | 0/17 | 0/4 | 0/6 | 0/6 | 1/23 | 0/20 | 0/7 | 0/41 | 0/21 |
| Neutrophil count decreasedInvestigations | 0/6 | 0/17 | 0/4 | 1/6 | 0/6 | 0/23 | 0/20 | 0/7 | 0/41 | 1/21 |
| Platelet count decreasedInvestigations | 0/6 | 0/17 | 0/4 | 1/6 | 1/6 | 0/23 | 0/20 | 1/7 | 0/41 | 0/21 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 1/17 | 0/4 | 0/6 | 0/6 | 1/23 | 0/20 | 1/7 | 1/41 | 0/21 |
| Suicidal ideationPsychiatric disorders | 0/6 | 0/17 | 0/4 | 0/6 | 0/6 | 0/23 | 1/20 | 1/7 | 0/41 | 0/21 |
| Event | Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN | Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN | Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | Phase 1, Dose Escalation Cohort 2 + Dose Expansion: Palbociclib 75 mg/m^2 + TMZ + IRN | Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX | TSC: Palbociclib 75 mg/m^2 + TOPO + CTX | Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ | Phase 2: IRN + TMZ |
|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/6 | 14/17 | 2/4 | 4/6 | 4/6 | 15/23 | 19/20 | 7/7 | 11/41 | 6/21 |
| DiarrhoeaGastrointestinal disorders | 5/6 | 13/17 | 4/4 | 4/6 | 2/6 | 18/23 | 5/20 | 5/7 | 12/41 | 9/21 |
| VomitingGastrointestinal disorders | 3/6 | 12/17 | 4/4 | 3/6 | 1/6 | 15/23 | 11/20 | 4/7 | 14/41 | 5/21 |
| Neutrophil count decreasedInvestigations | 3/6 | 16/17 | 2/4 | 5/6 | 6/6 | 19/23 | 16/20 | 5/7 | 18/41 | 8/21 |
| Platelet count decreasedInvestigations | 0/6 | 12/17 | 1/4 | 4/6 | 6/6 | 12/23 | 17/20 | 6/7 | 8/41 | 5/21 |
| White blood cell count decreasedInvestigations | 1/6 | 13/17 | 2/4 | 4/6 | 5/6 | 14/23 | 16/20 | 4/7 | 8/41 | 5/21 |
| NauseaGastrointestinal disorders | 4/6 | 13/17 | 3/4 | 4/6 | 4/6 | 17/23 | 14/20 | 5/7 | 11/41 | 4/21 |
| Lymphocyte count decreasedInvestigations | 1/6 | 10/17 | 1/4 | 3/6 | 4/6 | 11/23 | 14/20 | 3/7 | 5/41 | 0/21 |
| Decreased appetiteMetabolism and nutrition disorders | 3/6 | 2/17 | 2/4 | 4/6 | 1/6 | 5/23 | 3/20 | 1/7 | 0/41 | 0/21 |
| HeadacheNervous system disorders | 2/6 | 4/17 | 1/4 | 4/6 | 2/6 | 6/23 | 7/20 | 1/7 | 0/41 | 0/21 |
Baseline data are reported for FAS. "Number(no.) Analyzed"=no. of participants(ppts) included in FAS for Phase(P)1, TSC, P2 independently. Per protocol, two ppts with recurrent/refractory neuroblastoma (NB)from P1 were counted toward additional 5 ppts enrolled in NB TSC, for a total of 7 ppts required for Stage 1. To provide complete FAS of each cohort, these ppts are included in "No. Analyzed" counts for both P1 \& TSC. To avoid duplicate counting, "N" for "P 1 + TSC" includes only unique ppts.
| Age, Customized(Participants) | Phase 1 + TSC | Phase 2 | Total |
|---|---|---|---|
| Phase 1, Dose Escalation Cohort 1 — <= 6 years | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 1 — >6 to <12 years | 1 | — | 1 |
| Phase 1, Dose Escalation Cohort 1 — >=12 to <18 Years | 2 | — | 2 |
| Phase 1, Dose Escalation Cohort 1 — >=18 years | 1 | — | 1 |
| Phase 1, Dose Escalation Cohort 2 — <= 6 years | 1 | — | 1 |
| Phase 1, Dose Escalation Cohort 2 — >6 to <12 years | 1 | — | 1 |
| Phase 1, Dose Escalation Cohort 2 — >=12 to <18 Years | 2 | — | 2 |
| Phase 1, Dose Escalation Cohort 2 — >=18 years | 2 | — | 2 |
| Phase 1, Dose Escalation Cohort 3 — <= 6 years | 1 | — | 1 |
| Phase 1, Dose Escalation Cohort 3 — >6 to <12 years | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 3 — >=12 to <18 Years | 4 | — | 4 |
| Phase 1, Dose Escalation Cohort 3 — >=18 years | 1 | — | 1 |
| Phase 1, Dose Expansion Cohort 4 — <= 6 years | 5 | — | 5 |
| Phase 1, Dose Expansion Cohort 4 — >6 to <12 years | 3 | — | 3 |
| Phase 1, Dose Expansion Cohort 4 — >=12 to <18 Years | 8 | — | 8 |
| Phase 1, Dose Expansion Cohort 4 — >=18 years | 1 | — | 1 |
| Phase 1, Dose Determination Cohort 5 — <= 6 years | 1 | — | 1 |
| Phase 1, Dose Determination Cohort 5 — >6 to <12 years | 2 | — | 2 |
| Phase 1, Dose Determination Cohort 5 — >=12 to <18 Years | 1 | — | 1 |
| Phase 1, Dose Determination Cohort 5 — >=18 years | 2 | — | 2 |
| Phase 1, Dose Expansion Cohort 6 — <= 6 years | 5 | — | 5 |
| Phase 1, Dose Expansion Cohort 6 — >6 to <12 years | 6 | — | 6 |
| Phase 1, Dose Expansion Cohort 6 — >=12 to <18 Years | 7 | — | 7 |
| Phase 1, Dose Expansion Cohort 6 — >=18 years | 2 | — | 2 |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — <= 6 years | 3 | — | 3 |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — >6 to <12 years | 3 | — | 3 |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — >=12 to <18 Years | 1 | — | 1 |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — >=18 years | 0 | — | 0 |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — <= 6 years | — | 6 | 6 |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — >6 to <12 years | — | 7 | 7 |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — >=12 to <18 Years | — | 23 | 23 |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — >=18 years | — | 6 | 6 |
| Phase 2: IRN + TMZ — <= 6 years | — | 1 | 1 |
| Phase 2: IRN + TMZ — >6 to <12 years | — | 4 | 4 |
| Phase 2: IRN + TMZ — >=12 to <18 Years | — | 13 | 13 |
| Phase 2: IRN + TMZ — >=18 years | — | 3 | 3 |
| Sex: Female, Male(Participants) | Phase 1 + TSC | Phase 2 | Total |
|---|---|---|---|
| Phase 1, Dose Escalation Cohort 1 — Female | 2 | — | 2 |
| Phase 1, Dose Escalation Cohort 1 — Male | 2 | — | 2 |
| Phase 1, Dose Escalation Cohort 2 — Female | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 2 — Male | 6 | — | 6 |
| Phase 1, Dose Escalation Cohort 3 — Female | 4 | — | 4 |
| Phase 1, Dose Escalation Cohort 3 — Male | 2 | — | 2 |
| Phase 1, Dose Expansion Cohort 4 — Female | 6 | — | 6 |
| Phase 1, Dose Expansion Cohort 4 — Male | 11 | — | 11 |
| Phase 1, Dose Determination Cohort 5 — Female | 3 | — | 3 |
| Phase 1, Dose Determination Cohort 5 — Male | 3 | — | 3 |
| Phase 1, Dose Expansion Cohort 6 — Female | 11 | — | 11 |
| Phase 1, Dose Expansion Cohort 6 — Male | 9 | — | 9 |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Female | 5 | — | 5 |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Male | 2 | — | 2 |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Female | — | 9 | 9 |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Male | — | 33 | 33 |
| Phase 2: IRN+TMZ — Female | — | 9 | 9 |
| Phase 2: IRN+TMZ — Male | — | 12 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1 + TSC | Phase 2 | Total |
|---|---|---|---|
| Phase 1, Dose Escalation Cohort 1 — Hispanic or Latino | 1 | — | 1 |
| Phase 1, Dose Escalation Cohort 1 — Not Hispanic or Latino | 3 | — | 3 |
| Phase 1, Dose Escalation Cohort 1 — Unknown or Not Reported | 0 | — | 0 |
| Phase 1,Dose Escalation Cohort 2 — Hispanic or Latino | 1 | — | 1 |
| Phase 1,Dose Escalation Cohort 2 — Not Hispanic or Latino | 5 | — | 5 |
| Phase 1,Dose Escalation Cohort 2 — Unknown or Not Reported | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 3 — Hispanic or Latino | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 3 — Not Hispanic or Latino | 6 | — | 6 |
| Phase 1, Dose Escalation Cohort 3 — Unknown or Not Reported | 0 | — | 0 |
| Phase 1, Dose Expansion Cohort 4 — Hispanic or Latino | 5 | — | 5 |
| Phase 1, Dose Expansion Cohort 4 — Not Hispanic or Latino | 11 | — | 11 |
| Phase 1, Dose Expansion Cohort 4 — Unknown or Not Reported | 1 | — | 1 |
| Phase 1, Dose Determination Cohort 5 — Hispanic or Latino | 1 | — | 1 |
| Phase 1, Dose Determination Cohort 5 — Not Hispanic or Latino | 5 | — | 5 |
| Phase 1, Dose Determination Cohort 5 — Unknown or Not Reported | 0 | — | 0 |
| Phase 1, Dose Expansion Cohort 6 — Hispanic or Latino | 2 | — | 2 |
| Phase 1, Dose Expansion Cohort 6 — Not Hispanic or Latino | 17 | — | 17 |
| Phase 1, Dose Expansion Cohort 6 — Unknown or Not Reported | 1 | — | 1 |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Hispanic or Latino | 1 | — | 1 |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Not Hispanic or Latino | 6 | — | 6 |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Unknown or Not Reported | 0 | — | 0 |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Hispanic or Latino | — | 5 | 5 |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Not Hispanic or Latino | — | 32 | 32 |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Unknown or Not Reported | — | 5 | 5 |
| Phase 2: IRN+TMZ — Hispanic or Latino | — | 3 | 3 |
| Phase 2: IRN+TMZ — Not Hispanic or Latino | — | 16 | 16 |
| Phase 2: IRN+TMZ — Unknown or Not Reported | — | 2 | 2 |
| Race (NIH/OMB)(Participants) | Phase 1 + TSC | Phase 2 | Total |
|---|---|---|---|
| Phase 1, Dose Escalation Cohort 1 — American Indian or Alaska Native | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 1 — Asian | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 1 — Native Hawaiian or Other Pacific Islander | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 1 — Black or African American | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 1 — White | 4 | — | 4 |
| Phase 1, Dose Escalation Cohort 1 — More than one race | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 1 — Unknown or Not Reported | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 2 — American Indian or Alaska Native | 1 | — | 1 |
| Phase 1, Dose Escalation Cohort 2 — Asian | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 2 — Native Hawaiian or Other Pacific Islander | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 2 — Black or African American | 2 | — | 2 |
| Phase 1, Dose Escalation Cohort 2 — White | 3 | — | 3 |
| Phase 1, Dose Escalation Cohort 2 — More than one race | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 2 — Unknown or Not Reported | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 3 — American Indian or Alaska Native | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 3 — Asian | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 3 — Native Hawaiian or Other Pacific Islander | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 3 — Black or African American | 0 | — | 0 |
| Phase 1, Dose Escalation Cohort 3 — White | 5 | — | 5 |
| Phase 1, Dose Escalation Cohort 3 — More than one race | 1 | — | 1 |
| Phase 1, Dose Escalation Cohort 3 — Unknown or Not Reported | 0 | — | 0 |
| Phase 1, Dose Expansion Cohort 4 — American Indian or Alaska Native | 0 | — | 0 |
| Phase 1, Dose Expansion Cohort 4 — Asian | 0 | — | 0 |
| Phase 1, Dose Expansion Cohort 4 — Native Hawaiian or Other Pacific Islander | 0 | — | 0 |
| Phase 1, Dose Expansion Cohort 4 — Black or African American | 0 | — | 0 |
| Phase 1, Dose Expansion Cohort 4 — White | 9 | — | 9 |
| Phase 1, Dose Expansion Cohort 4 — More than one race | 1 | — | 1 |
| Phase 1, Dose Expansion Cohort 4 — Unknown or Not Reported | 7 | — | 7 |
| Phase 1, Dose Determination Cohort 5 — American Indian or Alaska Native | 0 | — | 0 |
| Phase 1, Dose Determination Cohort 5 — Asian | 0 | — | 0 |
| Phase 1, Dose Determination Cohort 5 — Native Hawaiian or Other Pacific Islander | 0 | — | 0 |
| Phase 1, Dose Determination Cohort 5 — Black or African American | 1 | — | 1 |
| Phase 1, Dose Determination Cohort 5 — White | 4 | — | 4 |
| Phase 1, Dose Determination Cohort 5 — More than one race | 1 | — | 1 |
| Phase 1, Dose Determination Cohort 5 — Unknown or Not Reported | 0 | — | 0 |
| Phase 1, Dose Expansion Cohort 6 — American Indian or Alaska Native | 0 | — | 0 |
| Phase 1, Dose Expansion Cohort 6 — Asian | 0 | — | 0 |
| Phase 1, Dose Expansion Cohort 6 — Native Hawaiian or Other Pacific Islander | 0 | — | 0 |
| Phase 1, Dose Expansion Cohort 6 — Black or African American | 2 | — | 2 |
| Phase 1, Dose Expansion Cohort 6 — White | 15 | — | 15 |
| Phase 1, Dose Expansion Cohort 6 — More than one race | 0 | — | 0 |
| Phase 1, Dose Expansion Cohort 6 — Unknown or Not Reported | 3 | — | 3 |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — American Indian or Alaska Native | 0 | — | 0 |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Asian | 1 | — | 1 |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Native Hawaiian or Other Pacific Islander | 0 | — | 0 |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Black or African American | 1 | — | 1 |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — White | 4 | — | 4 |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — More than one race | 1 | — | 1 |
| TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Unknown or Not Reported | 0 | — | 0 |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — American Indian or Alaska Native | — | 0 | 0 |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Asian | — | 12 | 12 |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Native Hawaiian or Other Pacific Islander | — | 0 | 0 |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Black or African American | — | 1 | 1 |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — White | — | 23 | 23 |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — More than one race | — | 0 | 0 |
| Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Unknown or Not Reported | — | 6 | 6 |
| Phase 2: IRN+TMZ — American Indian or Alaska Native | — | 0 | 0 |
| Phase 2: IRN+TMZ — Asian | — | 6 | 6 |
| Phase 2: IRN+TMZ — Native Hawaiian or Other Pacific Islander | — | 0 | 0 |
| Phase 2: IRN+TMZ — Black or African American | — | 0 | 0 |
| Phase 2: IRN+TMZ — White | — | 12 | 12 |
| Phase 2: IRN+TMZ — More than one race | — | 0 | 0 |
| Phase 2: IRN+TMZ — Unknown or Not Reported | — | 3 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from May 2019 to primary completion in Aug 2024, 63 months.
Results were first posted in Oct 2026, 2 years 1 month after primary completion.
Of 39 phase 2 interventional studies under Sarcoma, Ewing, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 92. This study's 63 months is above that.
Completion moved once since we started tracking on Sep 25, 2026: Oct 2025 → Aug 2025, on Oct 7, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Palbociclib · Temozolomide · Irinotecan · Topotecan · Cyclophosphamide